Real-world Evidence for EP2006 Multiple real-world studies and meta-analyses have contributed to the growing evidence supporting the efficacy and tolerability of EP2006 in patients with cancer undergoing chemotherapy. EP2006 consistently demonstrated greater cost-effectiveness compared with secondary prophylaxis with EP2006.